![]() |
|
|
Vol. 290, Issue 3, 1080-1084, September 1999
Department of Metabolism and Clinical Nutrition, Faculty of
Medicine, Kyoto University, Kyoto, Japan
Troglitazone is a new, orally effective antidiabetic agent that
decreases plasma glucose in obese patients with non-insulin-dependent diabetes mellitus. Unfortunately, troglitazone also has a propensity to
cause edema. This study was designed to determine how troglitazone affects intestinal ion transport and water absorption. Short circuit current (Isc) was measured in rat and human duodenal mucosa
in Ussing chambers. Five minutes later, the serosal addition of
troglitazone caused Isc to decrease gradually, and after 50 min, Isc reached the peak of decrease. EC50
values and maximum response to Isc in rat and human mucosa
were 8.4 and 8.7 µM and 8.56 ± 1.0 and 8.00 ± 2.0 µA/cm2, respectively. In an
HCO3
/CO2-free system, the
decrease in Isc caused by troglitazone was 1.31 ± 0.83 µA/cm2. When 10 mM acetazolamide was
preadministered, the small decrease in Isc evoked by
troglitazone (20 µM) was 4.56 ± 0.22 µA/cm2,
whereas the preadministration of 100 µM amiloride and 100 nM tetrodotoxin did not influence the decrease in Isc evoked
by troglitazone. The serosal preadministration of 100 nM vasoactive
intestinal peptide potently enhanced the decrease in Isc
evoked by 20 µM troglitazone (21.1 ± 1.63 µA/cm2). The cyclic AMP contents of rat duodenal mucosa
incubated with and without troglitazone (20 µM) for 50 min were
3.2 ± 0.25 and 5.8 ± 0.46 pmol/mg protein, respectively
(P < .01). These results indicate that the ionic
basis for the decrease in Isc that is induced by
troglitazone may be inhibition of electrogenic bicarbonate secretion.
The alteration of intestinal ion transport by troglitazone could
cause edema.
This article has been cited by other articles:
![]() |
E. Erdmann and R. G. Wilcox Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure Eur. Heart J., January 1, 2008; 29(1): 12 - 20. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhang, A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez, and T. Yang Collecting duct-specific deletion of peroxisome proliferator-activated receptor {gamma} blocks thiazolidinedione-induced fluid retention PNAS, June 28, 2005; 102(26): 9406 - 9411. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. Nesto, D. Bell, R. O. Bonow, V. Fonseca, S. M. Grundy, E. S. Horton, M. Le Winter, D. Porte, C. F. Semenkovich, S. Smith, et al. Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association Circulation, December 9, 2003; 108(23): 2941 - 2948. [Full Text] [PDF] |
||||